^
Association details:
| Biomarker: | JAK1 P429S |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
Excerpt:
A melanoma biopsy from the patient with the highest mutational load among the 9 non-responders (patient #15) had a somatic P429S missense mutation in the src-homology (SH2) domain of JAK1 (Fig. 1B).
DOI:
10.1158/2159-8290.CD-16-1223
